Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04200248 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of RBM-007 Alone and RBM-007 With Eylea® in Subjects With Wet Age-related Macular Degeneration
A Phase 2 study, sponsored by Ribomic USA.
- Completed
- Registry status
- Phase 2
- Development phase
- 94
- Enrollment target
NCT04200248: Completed Phase 2 study, sponsored by Ribomic USA.
NCT04200248 is a Phase 2 study that has completed, run by Ribomic USA. The registered enrollment target is 94 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (29% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04200248, a Phase 2 study, has completed, sponsored by Ribomic USA.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 94 participants
- Enrollment target
Study Summary
This is a multicenter, active-controlled, double masked study assessing the safety, efficacy and durability of four monthly intravitreal (IVT) injections of RBM-007 monotherapy, and four monthly RBM-007 injections in combination with Eylea® dosed at every other month, compared to Eylea® monotherapy dosed at every other month in approximately eighty-one subjects with exudative age-related macular degeneration (AMD).
Primary Outcome
Mean change in Best Corrected Visual Acuity from Baseline to Week 16
Interventions
- DRUG Aflibercept
- DRUG Sham
- DRUG RBM-007 Injectable Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2019-12-02 |
| Est. Completion | 2021-12-22 |
| Phase | Phase 2 |
What the finished NCT04200248 record still lists
NCT04200248 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 94 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (29% lower).
The record links to 0 conditions, and to 3 interventions - of which Aflibercept is the first listed.
NCT04200248 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04200248 about?
NCT04200248 is a clinical study titled "A Phase II Study of RBM-007 Alone and RBM-007 With Eylea® in Subjects With Wet Age-related Macular Degeneration". This is a multicenter, active-controlled, double masked study assessing the safety, efficacy and durability of four monthly intravitreal (IVT) injections of RBM-007 monotherapy, and four monthly RBM-007 injections in combination with Eylea® dosed at every other month, compared to Eylea® monotherapy ...
What is the current status of trial NCT04200248?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 94 participants. The study started on 2019-12-02. Estimated completion is 2021-12-22.
What interventions are being tested in trial NCT04200248?
The interventions under investigation include: Aflibercept (DRUG), Sham (DRUG), RBM-007 Injectable Solution (DRUG).
Who is sponsoring clinical trial NCT04200248?
This trial is sponsored by Ribomic USA, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04200248's enrollment target sits among peer trials
94 764th of 2000 higher than 1,235 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03747146 · 94 participants · NA
Enhanced Recovery After Surgery (ERAS) Total Knee Replacement (TKR) With a Transitional Pain Service
- NCT04061421 · 94 participants · Phase 1
Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)
- NCT04205968 · 94 participants · Phase 2
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
- NCT04464759 · 94 participants · Phase 1
A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI